Research programme: stem cell therapies - Promethera Biosciences

Drug Profile

Research programme: stem cell therapies - Promethera Biosciences

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Promethera Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency
  • Research Fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Oct 2017 Promethera Biosciences and Shibuya enter into collaboration to develop manufacturing platform for stem cell therapies for treatment of liver disorders
  • 21 Apr 2017 Pharmacodynamics data from preclinical studies in Liver disorders presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2017
  • 09 Jan 2017 Promethera Biosciences and LifeLiver enter into a strategic alliance to jointly develop H2Stem in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top